Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 4/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023540 | 0.88 | GAA (0.47) | ALDH1A1SMN1; SMN2LMNACFDPOLB | |
| SCHEMBL17032686 | 0.85 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2LMNAPOLBL3MBTL1 | |
| SCHEMBL17023365 | 0.85 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2LMNACFDCREBBP | |
| SCHEMBL29869185 | 0.84 | KRAS (0.41) | ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL17023368 | 0.84 | KRAS (0.41) | ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL17023509 | 0.81 | GAA (0.58) | ALDH1A1SMN1; SMN2LMNAPOLBL3MBTL1 | |
| SCHEMBL17034509 | 0.81 | PSEN1 (0.48) | PLA2G4AALDH1A1SMN1; SMN2CREBBP | |
| SCHEMBL17023325 | 0.80 | MAOB (0.51) | ALDH1A1SMN1; SMN2CFD | |
| SCHEMBL17023502 | 0.79 | GAA (0.47) | PLA2G4AALDH1A1SMN1; SMN2LMNACFD | |
| SCHEMBL17032688 | 0.79 | CFD (0.44) | ALDH1A1SMN1; SMN2LMNACFDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017035352-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3110804-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015130830-A9 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015130830-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | PLA2G4A 1968/4885SLC22A12 3529/4885ALDH1A1 2381/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | PLA2G4A 1968/4885SLC22A12 3529/4885ALDH1A1 2381/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | PLA2G4A 1968/4885SLC22A12 3529/4885ALDH1A1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.